Fundz

Octave Bioscience reported raising $31.8 Million in an initial SEC Form D filing, from an offering of $53.7 Million

PRIVATEMar 24, 2025$31.8M of $53.7M raised

Amount Raised

$31.8 Million

$31.8 Million sold, per SEC Form D (first sale Mar 7, 2025)

Round Type

Venture

Menlo ParkBiotechnologyHealthcare

Investors

Hikma VenturesIntermountain VenturesValhalla FoundationNovartisMerck Global Health Innovation FundCasdin CapitalS32Northpond VenturesBlue Venture FundByers Capital

Who else raised in Healthcare and Biotechnology around the same time

Companies in the same sectors as Octave Bioscience that raised within 45 days of this round, from Fundz verified event records.

  • Alessa Therapeutics raised $25M on April 18, 2025.
  • Singletto raised $10M on April 15, 2025.
  • Flyte raised $137K (Seed) on April 15, 2025.
  • Shape Memory Medical raised $4.4M (Series C) on April 15, 2025.
  • Akadeum Life Sciences raised $5.6M on April 11, 2025.
  • Talphera, Inc. raised $4.9M (Seed) on April 2, 2025.

Who to call at Octave Bioscience, and when

A new round usually means Octave Bioscience is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Octave Bioscience raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Octave Bioscience, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Octave Bioscience. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Octave Bioscience

Location

Menlo Park, California, United States

About

Octave Bioscience, Inc. is a commercial growth stage precision medicine company pioneering biomarker-driven solutions for neurodegenerative diseases, with an initial focus on Multiple Sclerosis, and Parkinson’s Disease in partnership with the Michael J. Fox Foundation. Octave’s comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Octave Bioscience raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsMelinda T., Director hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Octave Bioscience's next move

See what Strategic adds

Octave Bioscience raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.